Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Roschewski, Mark, Lionakis, Michail S., Sharman, Jeff P., Roswarski, Joseph, Goy, Andre, Monticelli, M. Andrew, Roshon, Michael, Wrzesinski, Stephen H., Desai, Jigar V., Zarakas, Marissa A., Collen, Jacob, Rose, Keith, Hamdy, Ahmed, Izumi, Raquel, Wright, George W., Chung, Kevin K., Baselga, Jose, Staudt, Louis M., Wilson, Wyndham H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274761/
https://www.ncbi.nlm.nih.gov/pubmed/32503877
http://dx.doi.org/10.1126/sciimmunol.abd0110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274761/
https://www.ncbi.nlm.nih.gov/pubmed/32503877
http://dx.doi.org/10.1126/sciimmunol.abd0110

Ejemplares similares